This Article Abstract Full Text (PDF) All Versions of this Article: 90/10/1087    most recent 01.RES.0000021114.92282.FAv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pare, G. Articles by Mendelsohn, M. E. Search for Related Content PubMed PubMed Citation Articles by Pare, G. Articles by Mendelsohn, M. E. Related Collections Animal models of human disease Genetically altered mice Smooth muscle proliferation and differentiation Other Vascular biology

(Circulation Research. 2002;90:1087.)
© 2002 American Heart Association, Inc.

Molecular Medicine

Estrogen Receptor- Mediates the Protective Effects of Estrogen Against Vascular Injury

Gary Pare, Andrée Krust^*, Richard H. Karas^*, Sonia Dupont, Mark Aronovitz, Pierre Chambon, Michael E. Mendelsohn

From the Molecular Cardiology Research Institute (G.P., R.H.K., M.A., M.E.M.), New England Medical Center, Boston, Mass; and Institut de Génétique et de Biologie Moléculaire et Cellulaire (A.K., S.D., P.C.), CNRS/INSERM/ULP, Collège de France, Illkirch Cedex, France.

Correspondence to Michael E. Mendelsohn, MD, New England Medical Center, 750 Washington St, #80, Boston, MA 0211. E-mail MMendelsohn{at}lifespan.org

	Abstract

Top Abstract Introduction Materials and Methods Results and Discussion References

 
Blood vessel cells express the 2 known estrogen receptors, and ß (ER, ERß), which are thought to mediate estrogen inhibition of vascular injury and atherosclerosis, but the relative role of ER and ERß in these events is controversial. Estrogen inhibits the vascular injury response to the same extent in ovariectomized female wild-type mice and in the original single gene knockout mice for ER (ERKO_{Chapel Hill} [ERKO_CH]) and ERß (ERßKO_{Chapel Hill} [ERßKO_CH]). In double gene knockout mice generated by crossing these animals (ER,ßKO_CH), estrogen no longer inhibits medial thickening after vascular injury, but still inhibits vascular smooth muscle cell proliferation and increases uterine weight. The partial retention of estrogen responsiveness in ER,ßKO_CH mice could be due either to the presence of a novel, unidentified estrogen receptor or to functional expression of an estrogen receptor- splice variant in the parental ERKO_CH mice. To distinguish between these possibilities, we studied recently generated mice fully null for estrogen receptor (ERKO_Strasbourg [ERKO_St]) and examined the effect of estrogen on the response to vascular injury. In the present study, we show that after vascular injury in ovariectomized ERKO_St mice, estrogen has no detectable effect on any measure of vascular injury, including medial area, proteoglycan deposition, or smooth muscle cell proliferation. These data demonstrate that estrogen receptor- mediates the protective effects of estrogen on the response to vascular injury.

Key Words: estrogen • hormones • vascular injury • receptors • animal models

	Introduction

Top Abstract Introduction Materials and Methods Results and Discussion References

 
The cardiovascular effects of steroid hormones are an area of intense interest at present. Estrogen has known systemic effects on circulating factors and has more recently been established to have direct effects on the blood vessel wall. Estrogen causes both rapid vascular dilatation and longer-term effects on gene expression in vascular cells (reviewed in Mendelsohn and Karas¹). At physiologically relevant concentrations of estrogen, studies support that estrogen receptors (ERs) and ß mediate both the rapid and the long-term cardiovascular effects of estrogen. ER and ERß are expressed in both vascular endothelial and smooth muscle cells, but their physiological roles in the vasculature are incompletely understood.

Using wild-type and estrogen receptor knockout mice, we have previously studied the role of ER and ERß in mediating the vascular protective effects of estrogen in a mouse carotid artery injury model.^2,3,5,6 Studies of mice harboring single gene deletions of either ER or ERß showed that treatment of ovariectomized female mice with nanomolar concentrations of 17ß-estradiol (E₂) inhibits the response to vascular injury to equivalent levels in wild-type mice, ERKO_{Chapel Hill} (ERKO_CH) and ERßKO_CH. ^2,5 These findings suggested that ER and ERß are able to complement one another such that each receptor alone is sufficient to mediate the vascular protective effects of estrogen, or that the vascular protective effects of estrogen are mediated by an ER/ERß-independent pathway. To distinguish between these 2 hypotheses, studies of vascular injury in ER,ßKO_CH (double) estrogen receptor knockout mice were performed.⁶ However, the effect of estrogen on vascular injury in these mice was complex. Although E₂ no longer inhibited the increases in medial carotid area after injury in the ER,ßKO_CH mice, E₂ still significantly inhibited vascular smooth muscle cell (VSMC) proliferation after injury. In addition, E₂ also caused a significant increase in uterine weight in the ER,ßKO_CH mice.⁶ These data showed that the role of estrogen receptors could diverge for specific components of the vascular injury response in the ER,ßKO_CH mice. However, the results left unresolved what is responsible for estrogen inhibition of VSMC proliferation and the increase in uterine weight in the ER,ßKO_CH mice. These could be due to an unidentified third estrogen receptor or to residual function of protein from an ER splice variant known to be expressed in the parental ERKO_CH mice.⁷ To resolve the question as to how estrogen inhibits vascular injury in the mouse carotid injury model, we have studied the effects of estrogen on the response to vascular injury in the newly created ERKO_Strasbourg (ERKO_St) mice.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results and Discussion References

 
Generation of ERKO_Strasbourg Mice
Full details have been described recently.⁸ In brief, to create mice fully null for ER, a targeting vector containing exon 3 of ER, a TKneo cassette, and a loxP site was generated using PCR-based site-directed mutagenesis, as described.⁸ The targeting vector was electroporated into 129/SvPas H1 embryonic stem (ES) cells, and after expansion of G418 neomycin-resistant clones, ES cells containing a targeted ER allele were identified and injected into C57BL/6 blastocysts. These were introduced into pseudopregnant hosts to obtain chimeric males that transmitted the mutation through crosses with C57BL/6 females, yielding heterozygous mice, which were next bred with homozygous CMV-Cre transgenic mice to generate heterozygous mice in which both ER exon 3 and the selectable marker were deleted. Inbreeding of heterozygous ER mice yielded mice homozygous for the deletion of ER exon 3 (ERKO_St mice), ⁸ in numbers consistent with Mendelian expectations. Institutional guidelines of the IACUC and DLAM were followed in the care and use of animals in this study.

Mouse Model of Carotid Arterial Injury
The mouse carotid injury model used in this study has been described and validated in detail.^2,3,5,6 The general study design, as previously, begins with ovariectomies of 10- to 12-week-old female mice 7 to 10 days before the start of the experiment. At day -7, vehicle- or E₂-releasing pellets (0.1 mg, 21-day release pellets, Innovative Research of America) were implanted in each animal. At Day 0, carotid injuries were performed, followed by implantation of osmotic minipumps calibrated to release BrdU over the course of the experiment (25 mg BrdU/kg per day), to allow measurement of the extent of vascular cell proliferation. Mice were killed at day 14. Bloods were harvested and blood vessels were fixed at physiological pressures (100 to 120 mm Hg), followed by analyses for each of the endpoints described, as previously.^2,3,5,6

Morphometry and Immunohistochemistry
Parallel sections from all 92 carotids (46 injured, 46 contralateral uninjured) were stained as described previously with hematoxylin-eosin and elastin, and area measurements were made using a computerized morphometric analysis system on the elastin-stained sections.³ BrdU-labeled cells were identified by immunostaining and were counted in all sections. Two independent observers fully blinded to treatment made all measurements. To distinguish between different vascular cell types, immunostaining also was performed on parallel carotid artery sections using endothelial cell–specific (factor VIII–related antigen) and VSMC-specific (-actin) antibodies.³ BrdU-positive cells were categorized as endothelial cells if they were positive for factor VIII–related antigen and negative for -actin, and as VSMCs if the converse pattern was seen. Proliferation Index is calculated as the ratio of BrdU-positive VSMCs to unstained medial nuclei in each section.⁶ Proteoglycan deposition was quantified using Movat’s pentachrome staining⁹ and computerized quantification of positive (blue) regions (Figure 2). For all statistical analyses, genotype and treatment groups were independent variables and thus analyzed using a 2-factor ANOVA, with post hoc pairwise comparisons made with the Student-Newman-Keuls test.

View larger version (61K): [in this window] [in a new window]   Figure 2. Representative sections stained for measurement of medial area (elastin stain, a through c), detection of proteoglycan deposition (Movat’s pentachrome stain, d through f), or VSMC proliferation (BrdU immunostain, g through i). In c, arrows depict the internal (open arrow) and external (black arrow) elastic membranes used to demarcate the media for computerized morphometric analysis. In f, yellow arrow and dotted lines indicate a region of blue staining for proteoglycan deposition, which is also quantified by computerized morphometric analysis. VSMC proliferation is quantified by counting BrdU-labeled cells and identifying VSMCs and endothelial cells by cell-specific immunostaining in parallel sections. In i, yellow arrow indicates a BrdU-labeled VSMC. For further details, see text and references 2, 3, 5, and 6.

	Results and Discussion

Top Abstract Introduction Materials and Methods Results and Discussion References

 
ERKO_St mice and their wild-type (WT) littermates were used to study the effect of estrogen on the vascular response to injury.^2,3,5,6 Complete ablation of ER in ERKO_St mice was confirmed by the absence in their uteri of any ER polypeptide immunoreactive with antibody directed against ER C-terminus, as well as by the absence of mRNA for ER-containing transcripts of any exons located downstream of exon 2.⁸ The mouse carotid injury model involves the uniform passage of a fine wire into the common carotid artery, causing endothelial denudation and an injury response characterized by increases in medial area and VSMC proliferation.^3,10

The response to vascular injury was studied in 46 normocholesterolemic, ovariectomized adult female mice (21 ERKO_St and 25 WT littermates) randomized to receive vehicle alone or 17ß-estradiol (E₂), as described.^2–6 No differences in the total or HDL cholesterol levels or triglycerides were noted between the experimental groups (Table). Estrogen levels were undetectable in vehicle-treated mice. Estrogen-treated animals attained mean circulating estrogen levels of 90 to 117 pg/mL (0.33 to 0.43 nmol/L). Uterine weights were low in both vehicle-treated WT and ERKO_St mice (Table and Figure 1). In WT mice, E₂ caused an increase in uterine weight from 9.4±0.5x10^-3 to 110.5±7.2x10^-3 g (P<0.001). In contrast, E₂ had no effect on ERKO_St uterine weights (Figure 1).

View this table: [in this window] [in a new window]   Table 1. Circulating Plasma Estrogen and Lipid Levels for the Experimental Mouse Groups

View larger version (14K): [in this window] [in a new window]   Figure 1. Uterine weights of wild-type and ERKOSt mice treated with vehicle or 17ß-estradiol. Mice received either placebo pellets (-E2), or 17ß-estradiol–containing pellets (+E2) for a total of 3 weeks before harvest. Wet weights of uteri were determined at the time of euthanasia in wild-type and ERKOSt mice. The 11.8-fold mean increase in uterine weight in the WT, +E2 group is highly significant compared with the WT, -E2 group (P<0.001).

Uninjured (Uninj) carotid arteries from WT and ERKO_St mice were indistinguishable by all morphometric criteria measured, whether treated with vehicle or E₂. As expected for this vascular injury model, which is characterized by medial thickening and VSMC proliferation,^2,5 only a negligible intimal response was evident after the endothelial denudation injury. Only 2 of the 46 injured vessels examined demonstrated any significant formation of neointima, and 1 injured carotid artery demonstrated evidence of thrombosis in situ. Injury led to a significant increase in medial area of both WT and ERKO_St carotid arteries (Figures 2a through 2c and 3A). In the WT mice, the medial area per section increased from 18.2±0.8x10^-3 to 27.9±2.8x10^-3 mm² after injury (P=0.001). As in previous studies,^2,3,5,6 estrogen replacement significantly inhibited the injury-induced increase in medial area in the WT mice to levels comparable to uninjured animals (to 20.8±1.3x10^-3 mm², P<0.001 versus Inj, -E₂; P=NS versus Uninj) (Figure 3A). In ERKO_St mice, significant injury was also noted, with the medial area per section increasing from 18.5±0.6x10^-3 to 22.0±0.8x10^-3 mm² after injury (P<0.05). However, estrogen replacement failed to inhibit this response in ERKO_St mice (Inj, +E₂=22.6±1.2x10^-3 mm², P=NS versus Inj, -E₂) (Figure 3A). The medial area thickening after injury in the vehicle-treated ERKO_St mice was significantly less than that of the vehicle-treated, WT mice (P=0.007) (Figure 3A).

View larger version (18K): [in this window] [in a new window]   Figure 3. Medial areas (A) and matrix deposition (B) in uninjured and injured carotid arteries from wild-type and ERKOSt mice treated with vehicle or 17ß-estradiol. Estrogen replacement significantly inhibited the injury-induced increase in medial area (A) and proteoglycan deposition (B) to levels comparable to the uninjured animals in wild-type mice (P<0.001), but failed to inhibit these responses in ERKOSt mice (P=NS). The medial area and proteoglycan deposition were determined by computerized morphometric analysis of full circumference sections from each animal. Bars represent the mean±SEM for each group. *P<0.05 vs the uninjured (Uninj) group within the same genotype.

The increase in medial area that occurs in response to vascular injury is due to an increase in both cellular proliferation and deposition of matrix proteins elaborated by vascular wall cells.¹¹ We quantified the extent of deposition of proteoglycan, one of the principal matrix substances elaborated, in carotid sections from all mice in the study (Figures 2d through 2f and 3B). In WT mice, the proteoglycan deposition per section rose from undetectable levels in uninjured vessels to 24.2±3.8% of total medial area after injury. Estrogen replacement significantly inhibited proteoglycan deposition in WT mice (to 7.6±1.9% of total area, P<0.001) (Figure 3B). In ERKO_St mice, proteoglycan deposition per section rose from undetectable levels in uninjured vessels to 16.3±2.8% of total medial area. Estrogen replacement failed to significantly inhibit this response in ERKO_St mice (Inj, -E₂=16.3±2.8% versus Inj, +E₂=13.5±2.1% of total medial area, P=NS; Figure 3B). The proteoglycan deposition per section in vehicle-treated ERKO_St mice was less than that in WT, vehicle-treated mice (P=0.02).

The extent of endothelial cell and VSMC proliferation over the 14 days after injury was quantified by immunostaining for 5-Bromo-2'-deoxyuridine (BrdU) in sections from both injured arteries and the contralateral uninjured vessels (Figures 2g through 2i and 4).^5,6 Injury induced significant increases in endothelial cell labeling in both WT and ERKO_St mice, but the extent of endothelial cell labeling was not different for these groups, nor was it affected by estrogen treatment (cf. references 2, 3, 5, and 6). Medial VSMC cell proliferation was also quantified (Figure 4). In uninjured vessels from WT mice, very few (mean, <1 cell/section) cells were labeled. Injury resulted in a marked increase in the proliferation of medial VSMCs in WT animals (mean Proliferation Index⁶ (PI)=2.8±0.8, P<0.01; Figure 4). E₂ inhibited this increase significantly in the WT mice (to PI=0.9±0.3, P<0.05; Figure 4), although not completely to the level of uninjured vessels. Medial VSMC labeling also was negligible in the uninjured vessels from ERKO_St mice (<1 cell/section) and increased significantly after carotid artery injury (to 1.1±0.3, P<0.01; Figure 4). In contrast to their WT littermates, VSMC proliferation was not inhibited significantly by estrogen treatment in ERKO_St mice (mean=0.8±0.1, P=NS; Figure 4). The extent of VSMC proliferation was less in injured blood vessels from vehicle-treated ERKO_St mice than in those from WT, vehicle-treated mice (PI=1.1±0.3 versus 2.8±0.8, respectively, P<0.05; Figure 4). Thus, for all 3 measures of vascular injury response, the ovariectomized, vehicle-treated WT mice demonstrated greater injury responses than ERKO_St mice, and the protective effects of estrogen observed in the WT mice were absent in ERKO_St mice.

View larger version (18K): [in this window] [in a new window]   Figure 4. Vascular smooth muscle cell proliferation of uninjured and injured carotid arteries from wild-type and ERKOSt mice treated with vehicle or 17ß-estradiol. E2 inhibited VSMC proliferation significantly in the wild-type mice (P<0.05), although not completely to levels of uninjured vessels. In contrast to their wild-type littermates, VSMC proliferation was not inhibited significantly by estrogen treatment in the ERKOSt mice (P=NS). Bars represent the mean±SEM for each group. *P<0.01 vs the uninjured (Uninj) group within the same genotype.

Numerous studies to date implicate estrogen receptors in the regulation of the vascular protective effects of estrogen,^1,3–10 but remain inconclusive as to the relative roles of ER, ERß, and/or a potential third estrogen-responsive receptor in mediating this protection. ERKO_CH, the first ER knockout mice to be generated, were created by insertion of a neo gene into exon 2 of ER.⁴ ERKO_CH mice have marked reproductive phenotypes,^4,12 but also display a low level of residual, high-affinity estradiol binding, as well as expression of two ER-derived transcripts, one of which encodes a truncated ER with intact DNA- and hormone-binding domains. In contrast, ERKO_St mice are fully null.^7,8 ERKO_CH mice are protected against vascular injury equally well by physiological estrogen replacement as their WT littermates.² Mice generated with a disruption of ERß in both Chapel Hill (ERßKO_CH)⁵ and Strasbourg (ERßKO_St)⁸ both appear to be completely null for ERß and to have very similar reproductive phenotypes.^13,8 ERßKO_CH mice also are protected against vascular injury equally well by physiological estrogen replacement as their WT littermates.⁵ Finally, ER,ßKO_CH mice,⁶ generated by crossing ERKO_CH and ERßKO_CH mice, retain some estrogen responses in both uterine and vascular tissues.⁶

The present data show that ER mediates the inhibitory effects of E₂ on all injury responses measured in the mouse carotid vascular injury model. This resolves a longstanding debate in the literature regarding whether ERs mediate the vascular protective effects of estrogen at all, and addresses the relative importance of ER and ERß in these effects. ER and ERß are transcription factors that alter gene expression in both reproductive and nonreproductive target tissues, including liver, bone, brain, and the cardiovascular system.^1,14–16 The present findings highlight the potential importance of ER and ER-regulated genes in the protective effects of estrogen against vascular injury. Some likely ER-regulated gene candidates include estrogen-induced genes, such as endothelial NOS,¹⁷ cyclooxygenase-1,¹⁸ and matrix metalloproteinase-2,¹⁹ and estrogen-inhibited genes such as endothelin-1,^20,21 vascular adhesion molecules,²² and the angiotensin II receptor AT₁ ²³ (see also summary Tables in references^1,24,25). The loss of estrogen protection in the ERKO_St mice thus may be due in part to the altered expression of ER-regulated genes responsible for estrogen-mediated enhancement of endothelial cell proliferation.

Based on the present study and very recent work from several laboratories, a molecular explanation is now possible for the results reported here and previously.^2,6 The Korach laboratory⁷ originally reported that their ERKO_CH mice still encodes a variant ER transcript, corresponding to a partial deletion in the A/B domain of 64 amino acids and an insertion of 7 amino acids encoded by the neomycin insert. In heterologous expression studies, they showed that this transcript, which would encode a truncated, 55-kDa ER (ER55), retained estrogen-dependent transcriptional activity, although protein expression was not evaluated in the murine tissues. Recently, Flouriot and colleagues²⁶ characterized a new 46-kDa endogenous isoform of ER in nonvascular cells. This isoform, encoded by an ER transcript lacking the first coding exon, is missing the N-terminal 173 amino acids of full-length ER, but retains transcriptional activity in the appropriate cell type. A separate study published while this article was under review and including those authors of this work responsible for construction of the ERKO_St mice (A.K., P.C.),²⁷ confirmed the presence of ER mRNA variants in ERKO_CH mice. In the aorta of ovariectomized wild-type mice, full-length ER transcript and another 540-bp PCR product were detected, the latter resulting from splicing of exon 1 such that it would encode an ER46 isoform deleted for the A/B domain, as reported previously by the Gannon laboratory.²⁶ No RT-PCR products were generated from mRNA obtained in the aorta of the ERKO_St mutant mice in this study, but 3 unique RT-PCR products were detected in the aorta of ERKO_CH mice.²⁷ Sequencing revealed that 1 was identical to the 540-bp splice variant found in wild-type mice and 2 were those reported previously by Couse et al,⁷ including 1 predicted to encode chimeric ER55. These investigators go on to show expression of a 55-kDa protein in both uterus and aorta of ERKO_CH mice using a C-terminal ER antibody.²⁷

Taken together, the available data now support that the ERKO_CH mice express a truncated isoform of ER in the vasculature that can mediate several physiological functions. The isoform expressed in ERKO_CH mice, which lacks the AF-1 of ER, is sufficient to mediate the effect of E₂ on the uterine response (present study and Pendaries et al²⁷), the endothelial production of NO,²⁷ and the inhibition of smooth muscle proliferation, but not the carotid medial thickening in response to injury.^2,6 It may therefore be useful to reexamine at least some prior studies in which ERKO_CH mice were used to study estrogen action in target tissues.²⁸ Data now exist to support that ER mediates 3 effects of estrogen in the vessel wall, including acceleration of reendothelialization, ²⁹ alteration of endothelial NO production,²⁷ and inhibition of the vascular injury response reported here. It is important to note that there is also a recently identified role for ERß in vascular physiology and the control of blood pressure. ERßKO mice demonstrate widespread vascular abnormalities and develop hypertension as they age.³⁰ Thus, both ER and ERß mediate physiologically important effects in the vasculature.

Wild-type mice uniformly displayed the largest vascular injury response for all parameters measured in the studies reported here. These animals, unlike the other groups, have an unliganded ER, which is known to be activated by estrogen-independent pathways that can lead to changes in the expression of a different set of genes than those recruited by estrogen-bound ER.^31–33 This raises the possibility that ligand-independent activation of ER contributes to the pronounced vascular injury response observed in vehicle-treated WT mice. This might be relevant to the recognized increase in ischemic cardiovascular diseases that occurs in postmenopausal women,^34–36 in whom there is an analogous unliganded estrogen receptor. In summary, the present study shows that ER mediates the inhibition of the vascular injury response by estrogen. These data help resolve the longstanding debate regarding the role of estrogen receptors, and the relative roles of ER and ERß, in the protective effects of estrogen against the vascular injury response. They also suggest that identification of novel vascular cell-specific ER agonists may prove to be useful therapeutic agents in cardiovascular diseases.

	Acknowledgments

 
This work was supported in part by NIH SCOR in Ischemic Heart Disease P50 HL63494; NIH R01 HL55309 and NIH R01 HL56069 (M.E.M.); NIH R01 HL61298 (R.H.K.); and by funds from the Center National de la Recherche Scientifique, The Institut National de la Santé et de la Recherche Médicale, the Collège de France, The Hôpital Universitaire de Strasbourg, The Association pour la Recherche sur le Cancer, the Fondation pour la Recherche Médicale, the Human Frontiers Science Program, the Ministère de la Recherche, and the European Economic Community. We thank Sharon M. Lynch for expert technical assistance. Requests for animals should be addressed to P. Chambon (E-mail chambon@igbmc.u-strasbg.fr).

	Footnotes

 
*Both authors contributed equally to this study.

Received February 18, 2002; revision received April 25, 2002; accepted April 26, 2002.

	References

Top Abstract Introduction Materials and Methods Results and Discussion References

 
1. Mendelsohn ME, Karas RH. Mechanisms of disease: the protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999; 340: 1801–1811.[Free Full Text]

2. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TRJr, Lubhan DB, O’Donnell TFJr, Korach KS, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor-–deficient mice. Nat Med. 1997; 3: 545–548.[CrossRef][Medline] [Order article via Infotrieve]

3. Sullivan TRJr, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O’Donnell TFJr, Mendelsohn ME. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest. 1995; 96: 2482–2488.[Medline] [Order article via Infotrieve]

4. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A. 1993; 90: 11162–11166.[Abstract/Free Full Text]

5. Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, Gustafsson JÅ, Korach KS, Smithies O, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor ß-deficient female mice. Proc Natl Acad Sci U S A. 1999; 96: 15133–15136.[Abstract/Free Full Text]

6. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson J-A, Mendelsohn ME. The effects of estrogen on the vascular injury response in estrogen receptor, (double) knockout mice. Circ Res. 2001; 89: 534–539.[Abstract/Free Full Text]

7. Couse JF, Curtis SW, Washburn TF, Lindzey J, Golding TS, Lubahn DB, Smithies O, Korach KS. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol. 1995; 9: 1441–1454.[Abstract/Free Full Text]

8. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors (ER) and ß (ERß) on mouse reproductive phenotypes. Development. 2000; 127: 4277–4291.[Abstract]

9. Garvey W, Fathi A, Bigelow F, Carpenter B, Jimenez C. Improved Movat pentachrome stain. Stain Technol. 1986; 61: 60–62.[Medline] [Order article via Infotrieve]

10. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993; 73: 792–796.[Abstract/Free Full Text]

11. Ross R, Fuster V. The pathogenesis of atherosclerosis.In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996: 441–459.

12. Eddy EM, Washburn TF, Bunch DO, Goulding EH, Gladen BC, Lubahn DB, Korach KS. Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility. Endocrinology. 1996; 137: 4796–4805.[Abstract]

13. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson J-A, Smithies O. Generation and reproductive phenotype of mice lacking estrogen receptor ß. Proc Natl Acad Sci U S A. 1998; 95: 15677–15682.[Abstract/Free Full Text]

14. Walter P, Green S, Green G, Krust A, Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M, Chambon P. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A. 1985; 82: 7889–7893[Abstract/Free Full Text]

15. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. Overview, the nuclear receptor superfamily: the second decade. Cell. 1995; 83: 835–839.[CrossRef][Medline] [Order article via Infotrieve]

16. Tsai MJ, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann Rev Biochem. 1994; 63: 451–486.[CrossRef][Medline] [Order article via Infotrieve]

17. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A. 1994; 91: 5212–5216.[Abstract/Free Full Text]

18. Jun SS, Chen Z, Pace MC, Shaul PW. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J Clin Invest. 1998; 102: 176–183.[Medline] [Order article via Infotrieve]

19. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17ß-Oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta Mol Basis Dis. 1998; 1406: 169–174.[Medline] [Order article via Infotrieve]

20. Mikkola T, Viinikka L, Ylikorkala O. Estrogen and postmenopausal estrogen/progestin therapy: effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production. Eur J Obstet Gynecol Reprod Biol. 1998; 79: 75–82.[CrossRef][Medline] [Order article via Infotrieve]

21. Akishita M, Kozaki K, Eto M, Yoshizumi M, Ishikawa M, Toba K, Orimo H, Ouchi Y. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochem Biophys Res Comm. 1998; 251: 17–21.[CrossRef][Medline] [Order article via Infotrieve]

22. Caulin-Glaser T, Watson GA, Pardi R, Bender JR. Effects of 17ß-estradiol on cytokine-induced endothelial cell adhesion molecular expression. J Clin Invest. 1996; 98: 36–42.[Medline] [Order article via Infotrieve]

23. Nickenig G, Strehlow K, Wassmann S, Baumer AT, Albory K, Sauer H, Bohm M. Differential effects of estrogen and progesterone on AT₁ receptor gene expression in vascular smooth muscle cells. Circulation. 2000; 102: 1828–1833.[Abstract/Free Full Text]

24. Mendelsohn ME, Karas RH. Estrogen and the blood vessel wall. Curr Opin Cardiol. 1994; 9: 619–626.[Medline] [Order article via Infotrieve]

25. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996; 10: 615–624.[Abstract]

26. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F. Identification of a new isoform of the human estrogen receptor (hER) that is encoded by distinct transcripts and that is able to repress hER activation function 1. EMBO J. 2000; 19: 4688–4700.[CrossRef][Medline] [Order article via Infotrieve]

27. Pendaries C, Darblade B, Rochaix P, Krust A, Chambon P, Korach KS, Bayard F, Arnal JF. The AF-1 activation-function of ER may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci U S A. 2002; 99: 2205–2210.[Abstract/Free Full Text]

28. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999; 20: 358–417.[Abstract/Free Full Text]

29. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor- but not estrogen receptor-ß. Circulation. 2001; 103: 423–428.[Abstract/Free Full Text]

30. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox DA, Hodgin JB, Shaul PW, Thorén P, Smithies O, Gustafsson J-A, Mendelsohn ME. Abnormal vascular function and hypertension in mice deficient in estrogen receptor ß. Science. 2002;.

31. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270: 1491–1494.[Abstract/Free Full Text]

32. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996; 15: 2174–2183.[Medline] [Order article via Infotrieve]

33. Karas RH, Gauer EA, Bieber HE, Baur WE, Mendelsohn ME. Growth factor activation of the estrogen receptor in vascular cells occurs via a MAP kinase-independent pathway. J Clin Invest. 1998; 101: 2851–2861.[Medline] [Order article via Infotrieve]

34. Douglas PSE. Cardiovascular Health and Disease in Women. Philadelphia, Pa: W.B. Saunders Company; 1993.

35. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993; 329: 247–256.[Free Full Text]

36. Robertson RM. Women and cardiovascular disease: the risks of misperception and the need for action. Circulation. 2001; 103: 2318–2320.[Free Full Text]

This article has been cited by other articles:

				M. Burek, P. A. Arias-Loza, N. Roewer, and C. Y. Forster Claudin-5 as a Novel Estrogen Target in Vascular Endothelium Arterioscler Thromb Vasc Biol, February 1, 2010; 30(2): 298 - 304. [Abstract] [Full Text] [PDF]

				A. Billon-Gales, C. Fontaine, V. Douin-Echinard, L. Delpy, H. Berges, B. Calippe, F. Lenfant, H. Laurell, J.-C. Guery, P. Gourdy, et al. Endothelial Estrogen Receptor-{alpha} Plays a Crucial Role in the Atheroprotective Action of 17{beta}-Estradiol in Low-Density Lipoprotein Receptor-Deficient Mice Circulation, December 22, 2009; 120(25): 2567 - 2576. [Abstract] [Full Text] [PDF]

				K. Rayner, J. Sun, Y.-X. Chen, M. McNulty, T. Simard, X. Zhao, D. J. Wells, J. de Belleroche, and E. R. O'Brien Heat Shock Protein 27 Protects Against Atherogenesis via an Estrogen-Dependent Mechanism: Role of Selective Estrogen Receptor Beta Modulation Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1751 - 1756. [Abstract] [Full Text] [PDF]

				A. Billon-Gales, C. Fontaine, C. Filipe, V. Douin-Echinard, M.-J. Fouque, G. Flouriot, P. Gourdy, F. Lenfant, H. Laurell, A. Krust, et al. The transactivating function 1 of estrogen receptor {alpha} is dispensable for the vasculoprotective actions of 17{beta}-estradiol PNAS, February 10, 2009; 106(6): 2053 - 2058. [Abstract] [Full Text] [PDF]

				K. K. Schnoes, I. Z. Jaffe, L. Iyer, A. Dabreo, M. Aronovitz, B. Newfell, U. Hansen, G. Rosano, and M. E. Mendelsohn Research Resource: Rapid Recruitment of Temporally Distinct Vascular Gene Sets by Estrogen Mol. Endocrinol., November 1, 2008; 22(11): 2544 - 2556. [Abstract] [Full Text] [PDF]

				T. Lahm, P. R. Crisostomo, T. A. Markel, M. Wang, Y. Wang, J. Tan, and D. R. Meldrum Selective estrogen receptor-{alpha} and estrogen receptor-{beta} agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1486 - R1493. [Abstract] [Full Text] [PDF]

				A. Pedram, M. Razandi, D. Lubahn, J. Liu, M. Vannan, and E. R. Levin Estrogen Inhibits Cardiac Hypertrophy: Role of Estrogen Receptor-{beta} to Inhibit Calcineurin Endocrinology, July 1, 2008; 149(7): 3361 - 3369. [Abstract] [Full Text] [PDF]

				R. Matyal Newly Appreciated Pathophysiology of Ischemic Heart Disease in Women Mandates Changes in Perioperative Management: A Core Review Anesth. Analg., July 1, 2008; 107(1): 37 - 50. [Abstract] [Full Text] [PDF]

				V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF]

				C. Filipe, L. Lam Shang Leen, L. Brouchet, A. Billon, V. Benouaich, V. Fontaine, P. Gourdy, F. Lenfant, J.-F. Arnal, A.-P. Gadeau, et al. Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2822 - H2830. [Abstract] [Full Text] [PDF]

				K. Kublickiene, X.-D. Fu, E. Svedas, B.-M. Landgren, A. R. Genazzani, and T. Simoncini Effects in Postmenopausal Women of Estradiol and Medroxyprogesterone Alone and Combined on Resistance Artery Function and Endothelial Morphology and Movement J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1874 - 1883. [Abstract] [Full Text] [PDF]

				R. Lopez-Sepulveda, R. Jimenez, M. Romero, M. J. Zarzuelo, M. Sanchez, M. Gomez-Guzman, F. Vargas, F. O'Valle, A. Zarzuelo, F. Perez-Vizcaino, et al. Wine Polyphenols Improve Endothelial Function in Large Vessels of Female Spontaneously Hypertensive Rats Hypertension, April 1, 2008; 51(4): 1088 - 1095. [Abstract] [Full Text] [PDF]

				A. Billon, S. Lehoux, L. Lam Shang Leen, H. Laurell, C. Filipe, V. Benouaich, L. Brouchet, C. Dessy, P. Gourdy, A.-P. Gadeau, et al. The Estrogen Effects on Endothelial Repair and Mitogen-Activated Protein Kinase Activation Are Abolished in Endothelial Nitric-Oxide (NO) Synthase Knockout Mice, but Not by NO Synthase Inhibition by N-Nitro-L-arginine Methyl Ester Am. J. Pathol., March 1, 2008; 172(3): 830 - 838. [Abstract] [Full Text] [PDF]

				C. D. DuSell, M. Umetani, P. W. Shaul, D. J. Mangelsdorf, and D. P. McDonnell 27-Hydroxycholesterol Is an Endogenous Selective Estrogen Receptor Modulator Mol. Endocrinol., January 1, 2008; 22(1): 65 - 77. [Abstract] [Full Text] [PDF]

				G. Douglas, M. Natalia Cruz, L. Poston, J.-A. Gustafsson, and K. Kublickiene Functional characterization and sex differences in small mesenteric arteries of the estrogen receptor- knockout mouse Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R112 - R120. [Abstract] [Full Text] [PDF]

				Ma. E. D. Esqueda, T. Craig, and C. Hinojosa-Laborde Effect of Ovariectomy on Renal Estrogen Receptor-{alpha} and Estrogen Receptor-{beta} in Young Salt-Sensitive and -Resistant Rats Hypertension, October 1, 2007; 50(4): 768 - 772. [Abstract] [Full Text] [PDF]

				Y. Yuan and J. Xu Loss-of-Function Deletion of the Steroid Receptor Coactivator-1 Gene in Mice Reduces Estrogen Effect on the Vascular Injury Response Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1521 - 1527. [Abstract] [Full Text] [PDF]

				M. E. Mendelsohn and R. H. Karas HRT and the Young at Heart N. Engl. J. Med., June 21, 2007; 356(25): 2639 - 2641. [Full Text] [PDF]

				R. O'Lone, K. Knorr, I. Z. Jaffe, M. E. Schaffer, P. G. V. Martini, R. H. Karas, J. Bienkowska, M. E. Mendelsohn, and U. Hansen Estrogen Receptors {alpha} and {beta} Mediate Distinct Pathways of Vascular Gene Expression, Including Genes Involved in Mitochondrial Electron Transport and Generation of Reactive Oxygen Species Mol. Endocrinol., June 1, 2007; 21(6): 1281 - 1296. [Abstract] [Full Text] [PDF]

				D. Xing, W. Feng, A. P. Miller, N. M. Weathington, Y.-F. Chen, L. Novak, J. E. Blalock, and S. Oparil Estrogen modulates TNF-{alpha}-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2607 - H2612. [Abstract] [Full Text] [PDF]

				N. R. Ferreri Estrogen-TNF interactions and vascular inflammation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2566 - H2569. [Full Text] [PDF]

				T. Traupe, C. D. Stettler, H. Li, E. Haas, I. Bhattacharya, R. Minotti, and M. Barton Distinct Roles of Estrogen Receptors {alpha} and {beta} Mediating Acute Vasodilation of Epicardial Coronary Arteries Hypertension, June 1, 2007; 49(6): 1364 - 1370. [Abstract] [Full Text] [PDF]

				M. E. Wierman and W. M. Kohrt Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials Reproductive Sciences, May 1, 2007; 14(4): 300 - 314. [Abstract] [PDF]

				B. Xue, J. Pamidimukkala, D. B. Lubahn, and M. Hay Estrogen receptor-{alpha} mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1770 - H1776. [Abstract] [Full Text] [PDF]

				H. J. Li, Z. Haque, Q. Lu, L. Li, R. Karas, and M. Mendelsohn Steroid receptor coactivator 3 is a coactivator for myocardin, the regulator of smooth muscle transcription and differentiation PNAS, March 6, 2007; 104(10): 4065 - 4070. [Abstract] [Full Text] [PDF]

				H. A. Harris Estrogen Receptor-{beta}: Recent Lessons from in Vivo Studies Mol. Endocrinol., January 1, 2007; 21(1): 1 - 13. [Abstract] [Full Text] [PDF]

				Y. D. Krom, N. M.M. Pires, J. W. Jukema, M. R. de Vries, R. R. Frants, L. M. Havekes, K. W. van Dijk, and P. H.A. Quax Inhibition of neointima formation by local delivery of estrogen receptor alpha and beta specific agonists Cardiovasc Res, January 1, 2007; 73(1): 217 - 226. [Abstract] [Full Text] [PDF]

				K. Dahlman-Wright, V. Cavailles, S. A. Fuqua, V. C. Jordan, J. A. Katzenellenbogen, K. S. Korach, A. Maggi, M. Muramatsu, M. G. Parker, and J.-A. Gustafsson International Union of Pharmacology. LXIV. Estrogen Receptors Pharmacol. Rev., December 1, 2006; 58(4): 773 - 781. [Full Text] [PDF]

				K. Moriarty, K. H. Kim, and J. R. Bender Estrogen Receptor-Mediated Rapid Signaling Endocrinology, December 1, 2006; 147(12): 5557 - 5563. [Abstract] [Full Text] [PDF]

				H. Hamada, M. K. Kim, A. Iwakura, M. Ii, T. Thorne, G. Qin, J. Asai, Y. Tsutsumi, H. Sekiguchi, M. Silver, et al. Estrogen Receptors {alpha} and {beta} Mediate Contribution of Bone Marrow-Derived Endothelial Progenitor Cells to Functional Recovery After Myocardial Infarction Circulation, November 21, 2006; 114(21): 2261 - 2270. [Abstract] [Full Text] [PDF]

				P. A. Arias-Loza, K. Hu, A. Schafer, J. Bauersachs, T. Quaschning, J. Galle, V. Jazbutyte, L. Neyses, G. Ertl, K.-H. Fritzemeier, et al. Medroxyprogesterone Acetate But Not Drospirenone Ablates the Protective Function of 17{beta}-Estradiol in Aldosterone Salt-Treated Rats Hypertension, November 1, 2006; 48(5): 994 - 1001. [Abstract] [Full Text] [PDF]

				J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF]

				P. de Medina, N. Boubekeur, P. Balaguer, G. Favre, S. Silvente-Poirot, and M. Poirot The Prototypical Inhibitor of Cholesterol Esterification, Sah 58-035 [3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], Is an Agonist of Estrogen Receptors J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 139 - 149. [Abstract] [Full Text] [PDF]

				C. Bolego, E. Vegeto, C. Pinna, A. Maggi, and A. Cignarella Selective Agonists of Estrogen Receptor Isoforms: New Perspectives for Cardiovascular Disease Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2192 - 2199. [Abstract] [Full Text] [PDF]

				T. Simoncini, C. Scorticati, P. Mannella, A. Fadiel, M. S. Giretti, X.-D. Fu, C. Baldacci, S. Garibaldi, A. Caruso, L. Fornari, et al. Estrogen Receptor {alpha} Interacts with G{alpha}13 to Drive Actin Remodeling and Endothelial Cell Migration via the RhoA/Rho Kinase/Moesin Pathway Mol. Endocrinol., August 1, 2006; 20(8): 1756 - 1771. [Abstract] [Full Text] [PDF]

				R. C. Christian, P. Y. Liu, S. Harrington, M. Ruan, V. M. Miller, and L. A. Fitzpatrick Intimal Estrogen Receptor (ER){beta}, But Not ER{alpha} Expression, Is Correlated with Coronary Calcification and Atherosclerosis in Pre- and Postmenopausal Women J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2713 - 2720. [Abstract] [Full Text] [PDF]

				F. Hildebrand, W. J. Hubbard, M. A. Choudhry, B. M. Thobe, H.-C. Pape, and I. H. Chaudry Are the protective effects of 17{beta}-estradiol on splenic macrophages and splenocytes after trauma-hemorrhage mediated via estrogen-receptor (ER)-{alpha} or ER-{beta}? J. Leukoc. Biol., June 1, 2006; 79(6): 1173 - 1180. [Abstract] [Full Text] [PDF]

				M. R. Meyer, E. Haas, and M. Barton Gender Differences of Cardiovascular Disease: New Perspectives for Estrogen Receptor Signaling Hypertension, June 1, 2006; 47(6): 1019 - 1026. [Full Text] [PDF]

				K. Kublickiene, E. Svedas, B.-M. Landgren, M. Crisby, N. Nahar, H. Nisell, and L. Poston Small Artery Endothelial Dysfunction in Postmenopausal Women: In Vitro Function, Morphology, and Modification by Estrogen and Selective Estrogen Receptor Modulators J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6113 - 6122. [Abstract] [Full Text] [PDF]

				W. Koch, P. Hoppmann, A. Pfeufer, J. C. Mueller, A. Schomig, and A. Kastrati No Replication of Association Between Estrogen Receptor {alpha} Gene Polymorphisms and Susceptibility to Myocardial Infarction in a Large Sample of Patients of European Descent Circulation, October 4, 2005; 112(14): 2138 - 2142. [Abstract] [Full Text] [PDF]

				K. H. Kim and J. R. Bender Rapid, Estrogen Receptor-Mediated Signaling: Why Is the Endothelium So Special? Sci. Signal., June 14, 2005; 2005(288): pe28 - pe28. [Abstract] [Full Text] [PDF]

				M. E. Mendelsohn and R. H. Karas Molecular and Cellular Basis of Cardiovascular Gender Differences Science, June 10, 2005; 308(5728): 1583 - 1587. [Abstract] [Full Text] [PDF]

				X. Guo, M. Razandi, A. Pedram, G. Kassab, and E. R. Levin Estrogen Induces Vascular Wall Dilation: MEDIATION THROUGH KINASE SIGNALING TO NITRIC OXIDE AND ESTROGEN RECEPTORS {alpha} AND {beta} J. Biol. Chem., May 20, 2005; 280(20): 19704 - 19710. [Abstract] [Full Text] [PDF]

				M. J. Byers, A. Zangl, T. M. Phernetton, G. Lopez, D.-b. Chen, and R. R. Magness Endothelial vasodilator production by ovine uterine and systemic arteries: ovarian steroid and pregnancy control of ER{alpha} and ER{beta} levels J. Physiol., May 15, 2005; 565(1): 85 - 99. [Abstract] [Full Text] [PDF]

				R. K. Dubey, B. Imthurn, M. Barton, and E. K. Jackson Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen Cardiovasc Res, May 1, 2005; 66(2): 295 - 306. [Abstract] [Full Text] [PDF]

				J. Pamidimukkala, B. Xue, L. G. Newton, D. B. Lubahn, and M. Hay Estrogen receptor-{alpha} mediates estrogen facilitation of baroreflex heart rate responses in conscious mice Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1063 - H1070. [Abstract] [Full Text] [PDF]

				R. K. Dubey, E. K. Jackson, D. G. Gillespie, M. Rosselli, F. Barchiesi, A. Krust, H. Keller, L. C. Zacharia, and B. Imthurn Cytochromes 1A1/1B1- and Catechol-O-Methyltransferase-Derived Metabolites Mediate Estradiol-Induced Antimitogenesis in Human Cardiac Fibroblast J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 247 - 255. [Abstract] [Full Text] [PDF]

				M. Zaitseva, D. S. Yue, J. A. Katzenellenbogen, P. A. W. Rogers, and C. E. Gargett Estrogen Receptor-{alpha} Agonists Promote Angiogenesis in Human Myometrial Microvascular Endothelial Cells Reproductive Sciences, December 1, 2004; 11(8): 529 - 535. [Abstract] [PDF]

				Y. Nakamura, K. Igarashi, T. Suzuki, J. Kanno, T. Inoue, C. Tazawa, M. Saruta, T. Ando, N. Moriyama, T. Furukawa, et al. E4F1, a Novel Estrogen-Responsive Gene in Possible Atheroprotection, Revealed by Microarray Analysis Am. J. Pathol., December 1, 2004; 165(6): 2019 - 2031. [Abstract] [Full Text] [PDF]

				M. J. Polanczyk, R. E. Jones, S. Subramanian, M. Afentoulis, C. Rich, M. Zakroczymski, P. Cooke, A. A. Vandenbark, and H. Offner T Lymphocytes Do Not Directly Mediate the Protective Effect of Estrogen on Experimental Autoimmune Encephalomyelitis Am. J. Pathol., December 1, 2004; 165(6): 2069 - 2077. [Abstract] [Full Text] [PDF]

				S. C. E. Schuit, H.-H. S. Oei, J. C. M. Witteman, C. H. Geurts van Kessel, J. B. J. van Meurs, R. L. Nijhuis, J. P. T. M. van Leeuwen, F. H. de Jong, M. C. Zillikens, A. Hofman, et al. Estrogen Receptor {alpha} Gene Polymorphisms and Risk of Myocardial Infarction JAMA, June 23, 2004; 291(24): 2969 - 2977. [Abstract] [Full Text] [PDF]

				V. M. Miller, D. J. Tindall, and P. Y. Liu Of Mice, Men, and Hormones Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 995 - 997. [Full Text] [PDF]

				F. Barchiesi, E. K. Jackson, B. Imthurn, J. Fingerle, D. G. Gillespie, and R. K. Dubey Differential Regulation of Estrogen Receptor Subtypes {alpha} and {beta} in Human Aortic Smooth Muscle Cells by Oligonucleotides and Estradiol J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2373 - 2381. [Abstract] [Full Text] [PDF]

				M.-L. Gross, M. Adamczak, T. Rabe, N. A. Harbi, J. Krtil, A. Koch, P. Hamar, K. Amann, and E. Ritz Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats J. Am. Soc. Nephrol., February 1, 2004; 15(2): 348 - 358. [Abstract] [Full Text] [PDF]

				J. M. Orshal and R. A. Khalil Gender, sex hormones, and vascular tone Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R233 - R249. [Abstract] [Full Text] [PDF]

				M. E. Mendelsohn and G. M.C. Rosano Hormonal Regulation of Normal Vascular Tone in Males Circ. Res., December 12, 2003; 93(12): 1142 - 1145. [Full Text] [PDF]

				A. M. Shearman, L. A. Cupples, S. Demissie, I. Peter, C. H. Schmid, R. H. Karas, M. E. Mendelsohn, D. E. Housman, and D. Levy Association Between Estrogen Receptor {alpha} Gene Variation and Cardiovascular Disease JAMA, November 5, 2003; 290(17): 2263 - 2270. [Abstract] [Full Text] [PDF]

				J. Widder, T. Pelzer, C. von Poser-Klein, K. Hu, V. Jazbutyte, K.-H. Fritzemeier, C. Hegele-Hartung, L. Neyses, and J. Bauersachs Improvement of Endothelial Dysfunction by Selective Estrogen Receptor-{alpha} Stimulation in Ovariectomized SHR Hypertension, November 1, 2003; 42(5): 991 - 996. [Abstract] [Full Text] [PDF]

				H. A. Harris, L. M. Albert, Y. Leathurby, M. S. Malamas, R. E. Mewshaw, C. P. Miller, Y. P. Kharode, J. Marzolf, B. S. Komm, R. C. Winneker, et al. Evaluation of an Estrogen Receptor-{beta} Agonist in Animal Models of Human Disease Endocrinology, October 1, 2003; 144(10): 4241 - 4249. [Abstract] [Full Text] [PDF]

				P. Geraldes, M. G. Sirois, and J.-F. Tanguay Specific Contribution of Estrogen Receptors on Mitogen-Activated Protein Kinase Pathways and Vascular Cell Activation Circ. Res., September 5, 2003; 93(5): 399 - 405. [Abstract] [Full Text] [PDF]

				T. Watanabe, M. Akishita, T. Nakaoka, K. Kozaki, Y. Miyahara, H. He, Y. Ohike, T. Ogita, S. Inoue, M. Muramatsu, et al. Estrogen receptor {beta} mediates the inhibitory effect of estradiol on vascular smooth muscle cell proliferation Cardiovasc Res, September 1, 2003; 59(3): 734 - 744. [Abstract] [Full Text] [PDF]

				J. Frasor, D. H. Barnett, J. M. Danes, R. Hess, A. F. Parlow, and B. S. Katzenellenbogen Response-Specific and Ligand Dose-Dependent Modulation of Estrogen Receptor (ER) {alpha} Activity by ER{beta} in the Uterus Endocrinology, July 1, 2003; 144(7): 3159 - 3166. [Abstract] [Full Text] [PDF]

				S. A. Jelinsky, H. A. Harris, E. L. Brown, K. Flanagan, X. Zhang, C. Tunkey, K. Lai, M. V. Lane, D. K. Simcoe, and M. J. Evans Global Transcription Profiling of Estrogen Activity: Estrogen Receptor {alpha} Regulates Gene Expression in the Kidney Endocrinology, February 1, 2003; 144(2): 701 - 710. [Abstract] [Full Text] [PDF]

				T. Simoncini, E. Rabkin, and J. K. Liao Molecular Basis of Cell Membrane Estrogen Receptor Interaction With Phosphatidylinositol 3-Kinase in Endothelial Cells Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 198 - 203. [Abstract] [Full Text] [PDF]

				G. A. Figtree, D. McDonald, H. Watkins, and K. M. Channon Truncated Estrogen Receptor {alpha} 46-kDa Isoform in Human Endothelial Cells: Relationship to Acute Activation of Nitric Oxide Synthase Circulation, January 7, 2003; 107(1): 120 - 126. [Abstract] [Full Text] [PDF]

				J. B. Hodgin and N. Maeda Minireview: Estrogen and Mouse Models of Atherosclerosis Endocrinology, December 1, 2002; 143(12): 4495 - 4501. [Abstract] [Full Text] [PDF]

				K. J. Ho and J. K. Liao Nonnuclear Actions of Estrogen Arterioscler Thromb Vasc Biol, December 1, 2002; 22(12): 1952 - 1961. [Abstract] [Full Text] [PDF]

				X.-J. Du Clues to understanding the role of estrogen receptors in mediating cardiovascular protection Cardiovasc Res, October 1, 2002; 56(1): 4 - 7. [Full Text] [PDF]

				E. K. Jackson Commentary on Liu et al: Effect of Estrogen and AT1 Receptor Blocker on Neointima Formation Hypertension, October 1, 2002; 40(4): 448 - 450. [Full Text] [PDF]

				K. J. Ho and J. K. Liao Non-nuclear Actions of Estrogen: New Targets for Prevention and Treatment of Cardiovascular Disease Mol. Interv., July 1, 2002; 2(4): 219 - 228. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 90/10/1087    most recent 01.RES.0000021114.92282.FAv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pare, G. Articles by Mendelsohn, M. E. Search for Related Content PubMed PubMed Citation Articles by Pare, G. Articles by Mendelsohn, M. E. Related Collections Animal models of human disease Genetically altered mice Smooth muscle proliferation and differentiation Other Vascular biology